Oncotelic Therapeutics Inc - OTLC stock
About Oncotelic[edit]
Oncotelic Therapeutics, Inc (OTC:OTLC) is a pre-revenue stage pharmaceutical development company based in Agoura Hills, CA. The company is in the process of developing treatments for rare and orphan diseases and conditions. Currently, treatment development is in progress for COVID-19, Parkinson’s Disease, DIPG, and PDAC.[1]Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma ("DIPG" through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia ("AML" through OXi 4503). Oncotelic also acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our Annual Report on form 10-K/A filed with the SEC on April 19, 2023.
Development Pipeline[edit]
ArtiVeda/ArtiShield[edit]
This treatment is derived from the plant Artemisia, which has shown to be effective at safely inhibiting the the COVID-19 virus from multiplying. Artemisinin derivatives are used to treat malaria. More Information.[2]
OT-101[edit]
OT-101 is a treatment for both adult and pediatric brain tumors. Oncotelic submitted a clinical study protocol to the United States Food and Drug Administration in November, 2022, for the initiation of “G101”, which is a Phase 1 Trial for OT-101. OT-101 is a treatment for patients with recurrent or relapsed DMG. DMG in children is a very aggressive brain tumor with an expected survival rate of less than one year following radiation therapy.[3]
CA4P[edit]
CA4P is a vascular disrupting agent proposed for use in combination with Ipilimumab to treat solid tumors, particularly adult and pediatric melanoma. In May, 2020, Oncotelic received Rare Pediatric Disease Designation for CA4P from the FDA.[2]
Oxi4503[edit]
Oxi4503 is a treatment forf liquid tumors, particularly those associated with childhood leukemia. The FDA has granted the company’s request to designate OXi4503 for treatment of myeloid leukemia.[2]
AL-101[edit]
AL-101 is a treatment for Parkinson Disease via intranasal delivery of Apomorphine.[2]
Mergers, Acquisitions, Divestitures, and Partnerships[edit]
Mosaic ImmunoEngineering[edit]
In April, 2024, an agreement was signed with Mosaic ImmunoEngineering, Inc. regarding the sales of Oncotelic's "clinical stage necroptosis cancer therapies associated with Oncotelic’s vascular disruptive agents". Mosaic will acquire the rights to these therapies, along with Oncotelic's AI technologies for identifying immunotherapy combinations. In exchange, Mosaic will issue $15 million in shares to Oncotelic, with potential additional payments up to $15 million based on milestones.[4]
Shanghai Medicilon[edit]
Oncotelic has a strategic partnership with Shanghai Medicilon Inc. (688202.SH) to utilize Medicilon’s rapid IND development platform. The collaboration will support up to 20 Investigational New Drug (IND) projects, including six ongoing INDs focused on next-generation anticancer agents.[5]
Management[edit]
Vuong Trieu, PhD. – CEO and Chairman[edit]
Vuong Trieu served as President and CEO of Abraxane developer Igdrasol, Board Director of Cenomed, Director of Pharmacology, Pharmacokinetics, and Biology at Abraxis. He also led development in albumin encapsulated therapeutics, CNS drugs, and a platform for platform for small molecules, mirRNA, kinases.[6]
Amit Shah - CFO[edit]
Amit Shah served as Chief Financial Officer at publicly traded biotechnology company Marina Biotech, Inc., Vice President of Finance & Accounting and Acting CFO at Insightra Medical Inc., VP Finance and Acting Chief Financial Officer at IgDraSol Inc., Corporate Controller & Director of Finance at ISTA Pharmaceuticals. Controller at Spectrum Pharmaceuticals, Chief Financial Officer at management consulting firm Eagle Business Performance Services.[6]
Anthony Maida, Ph.D., MA, MBA, BA, BA – Chief Clinical Officer[edit]
Anthony Maida srved as Senior Vice President – Clinical Research for Northwest Biotherapeutics, Inc. with responsibility for operations oversight; Vice President of Clinical Research and General Manager, Oncology at PharmaNet, Inc.; Chairman and Director of BioConsul Drug Development Corporation. He also negotiated licensing agreements with top tier pharmaceutical firms including Astra Zeneca, Eli Lilly, RCT Corporation, Pfizer, MD Anderson, Novartis, Yale University, and Stanford University.[6]
- ↑ Yahoo Finance. OTLC Stock Quote. Retrieved on 12/1/2022.
- ↑ 2.0 2.1 2.2 2.3 Oncotelic.com. Oncotelic Pipeline. Retrieved on 12/1/2022.
- ↑ OTC Markets. Oncotelic Initiates Clinical Trials Evaluating OT-101 against Pediatric Gliomas. November 8, 2022.
- ↑ GlobeNewswire. Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc. April 29, 2024.
- ↑ GlobeNewswire. Oncotelic Accesses Rapid IND Development Platform through Partnership with Medicilon. February 25, 2025.
- ↑ 6.0 6.1 6.2 Oncotelic.com. About Us. Retrieved on 12/1/2022.
OTC Symbol: OTLC | OTC Tier: OTCQB
